{
    "nct_id": "NCT04404660",
    "official_title": "An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia",
    "inclusion_criteria": "* Age 18 years or older Age 18 years or older\n* ECOG performance status of 0 or 1\n* Relapsed or refractory B cell ALL\n* Patients with Ph+ ALL are eligible if intolerant to TKI, failed two lines of any TKI, or failed one line of second-generation TKI, or if TKI is contraindicated\n* Documented CD19 positivity within 1 month of screening\n* Phase Ib: Primary Cohort IA: Presence of ≥5% blasts in BM at screening\n* Phase Ib: Exploratory Cohort IB: MRD-positive defined as ≥ 1e-4 and <5% blasts in the BM at screening\n* Phase II: Primary Cohort IIA: Presence of ≥5% blasts in BM at screening\n* Phase II: Cohort IIB: ≥2nd CR or CRi with MRD-positive defined as ≥1e-3 by central ClonoSEQ® NGS testing and <5% blasts in the BM at screening\n* Adequate renal, hepatic, pulmonary, and cardiac function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Phase Ib (Cohort IA and Cohort IB) and Phase II (Cohort IIA and Cohort IIB) B-ALL with isolated EM disease\n* Diagnosis of Burkitt's leukaemia/lymphoma or CML lymphoid in blast crisis\n* History or presence of clinically relevant CNS pathology\n* Presence of CNS-3 disease or CNS-2 disease with neurological changes\n* Presence of active or uncontrolled fungal, bacterial, viral, or other infection requiring systemic antimicrobials for management\n* Active or latent Hepatitis B virus or active Hepatitis C virus\n* Human Immunodeficiency Virus (HIV), HTLV-1, HTLV-2, syphilis positive test\n* Prior CD19 targeted therapy other than blinatumomab. Patients who have experienced Grade 3 or higher neurotoxicity following blinatumomab.",
    "miscellaneous_criteria": ""
}